Management of del(5q) MDS

被引：1
|
作者：
Giagounidis, A. [1 ]
机构：
[1] St Johannes Hosp, Duisburg, Germany
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70035-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [21] Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)
    Gritsaev, S.
    Martinkevitch, I.
    Petrova, E.
    Kostroma, I.
    Ivanova, M.
    Sergeev, A.
    Tiranova, S.
    Potichonova, N.
    LEUKEMIA RESEARCH, 2013, 37 : S88 - S88
  • [22] CYTOGENETIC CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS) WITH ISOLATED DEL(5Q)
    Zemanova, Z.
    Michalova, K.
    Brezinova, J.
    Svobodova, K.
    Lhotska, H.
    Sarova, I.
    Lizcova, L.
    Izakova, S.
    Ransdorfova, S.
    Pavlistova, L.
    Berkova, A.
    Skipalova, K.
    Belickova, M.
    Siskova, M.
    Neuwirtova, R.
    Cermak, J.
    Stopka, T.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2017, 55 : S56 - S57
  • [23] REVelation (del: 5q)
    Sekeres, Mikkael A.
    BLOOD, 2009, 113 (17) : 3888 - 3889
  • [24] Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset
    Bowen, David
    Taylor, Adele
    Fenaux, Pierre
    Guerci-Bresler, Agnes
    Itzykson, Raphael
    Symeonidis, Argiris
    Kotsianidis, Ioannis
    Mittelman, Moshe
    Sanz, Guillermo
    Culligan, Dominic J.
    Cermak, Jaroslav
    Stauder, Reinhard
    Lindberg, Eva Hellstrom
    Malcovati, Luca
    Langemeijer, Saskia M. C.
    Germing, Ulrich
    Oster, Howard S.
    Madry, Krzysztof
    Holm, Mette Skov
    Smith, Alexandra
    van Marrewijk, Corine
    de Witte, Theo M.
    BLOOD, 2021, 138
  • [25] Role of lenalidomide in management of pure red cell aplasia (PRCA) and myelodysplastic syndromes (MDS) with del(5q)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A. M.
    LEUKEMIA RESEARCH, 2013, 37 : S100 - S100
  • [26] FAMILIAL MDS WITH 5Q - ABNORMALITY
    GRIMWADE, DJ
    STEPHENSON, J
    DESILVA, C
    DALTON, RG
    MUFTI, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (03) : 536 - 538
  • [27] THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
    Belickova, M.
    Vesela, J.
    Jonasova, A.
    Planetova, B.
    Valka, J.
    Mikulenkova, D.
    Zemanova, Z.
    Brezinova, J.
    Michalova, K.
    Cermak, J.
    LEUKEMIA RESEARCH, 2015, 39 : S22 - S23
  • [28] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein, Elan
    Weber, Urs M.
    Gore, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
  • [29] Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
    Beier, Fabian
    Kharabi Masouleh, Behzad
    Buesche, Guntram
    Ventura Ferreira, Monica S.
    Schneider, Rebekka K.
    Ziegler, Patrick
    Wilop, Stefan
    Vankann, Lucia
    Gattermann, Norbert
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Nolte, Florian
    Hofmann, Wolf-Karsten
    Haase, Detlef
    Kreipe, Hans
    Panse, Jens
    Blasco, Maria A.
    Germing, Ulrich
    Bruemmendorf, Tim H.
    LEUKEMIA RESEARCH, 2015, 39 (11) : 1292 - 1298
  • [30] Variability in the size of del(5q) and its clinical implication in myelodysplastic syndromes (MDS)
    Zemanova, Zuzana
    Sejgunovova, Nikola
    Svobodova, Karla
    Lhotska, Halka
    Vidlakova, Denisa
    Aghova, Tatiana
    Lizcova, Libuse
    Izakova, Silvia
    Mendlikova, Iveta
    Ransdorfova, Sarka
    Hodanova, Lucie
    Pavlistova, Lenka
    Belickova, Monika
    Brezinova, Jana
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 559 - 560
12345